
















The p53 tumor suppressor protein controls cell fate by 
inducing apoptosis or cell cycle arrest in response to 
cell stress [1]. Cell cycle arrest can be temporary 
(quiescent) or permanent (senescent) depending on p53 
regulation [2,3]. Under normal conditions, p53 binds to 
MDM2, which transports the protein to the cytoplasm 
where it undergoes rapid proteosomal degradation. A 
class of chemotherapeutic molecules called Nutlins 
inhibit p53-MDM2 interaction, and can therefore be 
used to control p53 activity in cancer cells [4]. In this 
issue of Aging, Korotchkina et al make use of nutlin-3a 
to dissect the mechanism by which p53 induces cellular 
senescence and quiescence [5]. The group demonstrates 
that p53-mediated senescence is irreversible in cells that 
maintain mTOR (mammalian target of rapamycn) 
signaling. However, when mTOR signaling is inhibited, 
activation of p53 leads to quiescence (Figure 1). These 
findings may have broad implications because the 
mTOR pathway is dysregulated in many forms of 
cancer [6]. 
 
Establishing the mechanisms involved in cell cycle 
arrest and cell dormancy is critical for understanding 
cancer cell proliferation. Demidenko et al. have 
previously demonstrated that despite its ability to 
induce cell cycle arrest, in some cell types p53 is a 
suppressor, not an inducer of cellular senescence [7]. 
They have also shown that cells (HT-p21-9) induced 
into senescence using an ITPG-inducible p21 
expression construct, were converted to quiescence in 
the presence of p53. In the same cells, nutlin-3a-
induction of p53 caused reversible cell cycle arrest, 
and cells resumed proliferation after removal of nutlin-
3a.  
 
The same group has also demonstrated that when the 


















induction of senescence. Addition of the TOR inhibitor 
rapamycin converted p21-induced senescent cells back 
to quiescence [7].  These findings suggest that activa-
tion of p53 sets in motion cell cycle arrest, after which 
its ability to exercise senescence is dependent on its 
interaction with the mTOR pathway. Senescence is 
achieved if p53 is incapable of disabling mTOR. 
Therefore, activating both mTOR and p53 in order to 
achieve a permanent state of cell dormancy, may prove 
to be a promising therapeutic strategy for treating 
cancer. In their current study, Korotchkina et al further 
explore the role of mTOR as a senescence-inducing 
factor. They show that nutlin-3a-induced senescent cells 
converted to a quiescent state when mTOR was 
inactivated with rapamycin (Figure 1). Furthermore, the 
authors show that in p53-mediated quiescent cells, 
depletion of TSC2, a negative regulator of mTOR, 
results in conversion to senescence. This body of work 
may also offer explanations as to the role that p53 plays 
in aging. Others have shown that p53 function declines 
with age [8,9], and mild activation of p53 may increase 
the lifespan of mice [10]. It will be interesting to further 
determine the interactions between p53 and mTOR in 
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Figure  1.  p53‐induced  senescence  or  quiescence.  Cell  stress  factors  or  nutlin‐3a
activates  p53.  Rapamycin  treatment  inhibits  mTOR  signaling  and  cells  enter  a  reversible
quiescent state. ShTSC2‐mediated activation of mTOR sends cells into senescence. 